



HAL
open science

Benefits and risks of transforming data from dynamic positron emission tomography, with an application to hepatic encephalopathy

Ludvik Bass, Susanne Keiding, Ole L. Munk

► **To cite this version:**

Ludvik Bass, Susanne Keiding, Ole L. Munk. Benefits and risks of transforming data from dynamic positron emission tomography, with an application to hepatic encephalopathy. *Journal of Theoretical Biology*, 2009, 256 (4), pp.632. 10.1016/j.jtbi.2008.10.022 . hal-00554524

HAL Id: hal-00554524

<https://hal.science/hal-00554524>

Submitted on 11 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Author's Accepted Manuscript

Benefits and risks of transforming data from dynamic positron emission tomography, with an application to hepatic encephalopathy

Ludvik Bass, Susanne Keiding, Ole L. Munk

PII: S0022-5193(08)00572-9
DOI: doi:10.1016/j.jtbi.2008.10.022
Reference: YJTBI5348

To appear in: *Journal of Theoretical Biology*

Received date: 10 July 2008
Revised date: 16 October 2008
Accepted date: 28 October 2008

Cite this article as: Ludvik Bass, Susanne Keiding and Ole L. Munk, Benefits and risks of transforming data from dynamic positron emission tomography, with an application to hepatic encephalopathy, *Journal of Theoretical Biology* (2008), doi:[10.1016/j.jtbi.2008.10.022](https://doi.org/10.1016/j.jtbi.2008.10.022)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



www.elsevier.com/locate/jtbi

Benefits and risks of transforming data from dynamic positron emission tomography, with an application to hepatic encephalopathy

Ludvik Bass¹, Susanne Keiding^{2,3}, Ole L. Munk^{2*}

¹ *Department of Mathematics, University of Queensland, Brisbane, Australia*

² *PET Center, Aarhus University Hospital, Aarhus, Denmark*

³ *Department of Medicine V, Aarhus University Hospital, Aarhus, Denmark*

* Corresponding Author

Accepted manuscript

Abstract

Transforming data sets to bring out expected model features can be valuable within limits and misleading outside them. Here we establish such limits for the widely used Gjedde-Patlak representation of dynamic PET data, with an application to hepatic encephalopathy.

Introduction

A representation of data acquired in dynamic positron emission tomography (PET), introduced by Gjedde (1982) and extended by Patlak et al. (1983), has been widely used since. This Gjedde-Patlak (GP) representation, pertaining to a class of models exemplified below, lends itself to an illuminating graphical analysis of the transformed data.

In the simplest of the relevant models, a PET tracer introduced into plasma with a time-dependent activity $c(t)$ enters tissue in a region of interest (ROI) with clearance K_1 . There it forms a pool of precursor with activity $M_1(t)$, which is metabolized irreversibly into the pool $M_2(t)$ with the rate constant k_3 , while also returning to plasma with the rate constant k_2 :

$$\frac{dM_1}{dt} = K_1 c - (k_2 + k_3) M_1 \quad (1)$$

$$\frac{dM_2}{dt} = k_3 M_1 \quad (2)$$

The initial conditions are

$$M_1(0) = M_2(0) = 0 \quad (3)$$

at $t = 0$ when tracer injection begins. The pools $M_1(t)$ and $M_2(t)$ may represent more complicated processes (Bender et al., 2001).

The activity of the ROI observed by PET is

$$M(t) = V_0 c(t) + M_1(t) + M_2(t) \quad (4)$$

where V_0 is the vascular volume in the ROI. Plasma activity $c(t)$ is usually sampled upstream of the organ of interest, but it is commonly taken to equal vascular activity throughout the ROI. Corrections to this convenient but unphysiological assumption have been developed (Munk et al., 2003), but they do not affect the present considerations.

The two observed quantities $M(t)$ and $c(t)$ are recorded typically for one hour. Nonlinear regression analysis of the resulting data aims at determining the kinetic constants V_0 , K_1 , k_2 , k_3 in each ROI from (1) – (4). In contrast, by introducing the ratio M/c and a transformed time as new variables, the GP representation permits the determination of certain combinations of the kinetic parameters from a more robust linear regression involving $M(t)$ only at late times.

In what follows we consider properties of the new variables and their effects on the data analysis.

Time Reversal on Plasma Upslope

The GP-transformed time variable is

$$\theta(t) = \frac{\int_0^t c(t') dt'}{c(t)} \quad (5)$$

for all positive t and $c(t)$. Clearly, to each time t there corresponds just one value of θ ; but is the converse true? Multiplying (5) through with c , differentiating with respect to time and re-arranging, we find

$$\frac{d\theta}{dt} = 1 - \frac{\theta}{c} \frac{dc}{dt} \quad (6)$$

On the downslope of the plasma curve (negative dc/dt) we have positive $d\theta/dt$, so that θ varies monotonically with t . But on the upslope there can occur temporary time-reversal, $d\theta/dt$ negative, for sufficiently steep dc/dt , as we show by an explicit example.

Let the earliest upslope of plasma activity be given by

$$c(t) = bte^{\alpha^2 t^2} \quad (7)$$

where b and α are positive constants. Substituting in (5) and integrating we find

$$\theta = \frac{1 - e^{-\alpha^2 t^2}}{2\alpha^2 t} \quad (8)$$

This θ grows as $\frac{1}{2} t$ for small αt , reaches a local maximum θ_{\max} ($0.319/\alpha$ at $1.118/\alpha$ approximately), and then declines as $1/(2\alpha^2 t)$ (Fig. 1, solid line). As t increases, $\theta(t)$ must pass through a minimum θ_{\min} (dotted line in Fig. 1) in order to attain a positive slope which reaches $d\theta/dt=1$ at the time t_p of the peak of plasma activity ($dc/dt=0$). Thus the transformed time θ elapses in the opposite direction to t between θ_{\min} and θ_{\max} . We believe this to be the first time-reversal seen in the biosciences.

For any $f(t)$ (such as M/c)

$$\frac{df(t)}{dt} = \frac{df(\theta)}{d\theta} \left(\frac{d\theta}{dt} \right) \quad (9)$$

so that, whenever $d\theta/dt < 0$, a function rising (falling) with t is falling (rising) with θ . To every θ between θ_{\min} and θ_{\max} in Fig. 1 there correspond three values of t , each with its ordinate $f(t)$. The GP representation thus transforms a monotonic $f(t)$ into an S-shaped $f(\theta)$, which is three-valued in the interval $\theta_{\min} < \theta < \theta_{\max}$. When $f(t)$ stands for $M(t)/c(t)$, it is apparent that the GP representation is not helpful on a steep plasma upslope.

Time-reversal is prevented by plasma activity rising sufficiently slowly. Thus, reducing α in the foregoing example so that

$$\frac{1.118}{\alpha} > t_p \quad (10)$$

is sufficient to remove the domain of time-reversal in Fig. 1. This will be so for boluses that pass through the heart before reaching a brain ROI (Keiding et al., 2006), but may not be so when a 0.2 mL bolus is injected directly into the carotid artery (Phelps et al., 1977). Data points on multiple-valued $M(\theta)/c(\theta)$ seen in GP plots at early times would probably be attributed to experimental errors.

Thus the inclusion of early data in GP plots requires injections which are sufficiently slow, as in (10). Rapid injections (e.g., intracarotid) succeed, without GP or related plots, at the exceptional extreme when the total amount of injected tracer that enters the ROI is present within the detector field of view at the instant at which the maximum count rate occurs (Raichle and Larson, 1981).

Spurious Metabolism on Plasma Downslope

The GP plot of M/c against θ can have an asymptote at late times (Gjedde, 1982):

$$\frac{M}{c} = V_0 + K_1 \frac{k_2}{(k_2 + k_3)^2} + K_1 \frac{k_3}{k_2 + k_3} \theta \quad (11)$$

which holds under conditions outlined below. The widest use of the GP representation (11) is the determination of the metabolic clearance, the coefficient of θ , (slope, K) and of the sum of the first two terms (intercept, V) by linear regression. This avoids the use of problematic early data, which must be included in non-linear regressions determining, from (1) – (4), all the kinetic parameters.

A non-metabolized diffusible PET tracer, such as (^{11}C)methylglucose, has $k_3=0$ and $M_2=0$, which reduces (11) to

$$\frac{M(t)}{c(t)} - V_0 = \frac{M_1(t)}{c(t)} = \frac{K_1}{k_2} \quad (12)$$

This special case suffices to focus on the quasi-steady assumption underlying all GP asymptotics. In the domain of the asymptote, $M_1(t)$ must depend on time in the same way as $c(t)$ (and approach zero in the same way) for M/c to tend to the constant in (12). On the other hand, substituting (12) in (1) we deduce that M_1 is independent of time ($dM_1/dt=0$). The use of θ in place of t does not change these considerations on the downslope (Sect. 2).

To resolve this contradiction as simply as possible we represent $c(t)$ asymptotically by a “final exponential” (Lassen and Sejrsen, 1971; Bass et al., 1984): $-(dc/dt)/c = \beta = \text{const.}$, take the time-derivative of M_1/c and use (1) with $k_3 = 0$:

$$\frac{d}{dt} \left(\frac{M_1}{c} \right) = K_1 - (k_2 - \beta) \frac{M_1}{c} \quad (13)$$

With $M_1(0)=0$ from (3), integration of (13) gives

$$\frac{M_1}{c} = \frac{K_1}{k_2 - \beta} \left[1 - e^{-(k_2 - \beta)t} \right] \quad (14)$$

For $k_2 > \beta$ we find a horizontal asymptote with ordinate $K_1/(k_2 - \beta)$ (Fig. 2, lowest line), which is more accurate than (12) but approaches it when β is small compared with k_2 . Here the inequality $k_2 > \beta$ ensures that $c(t)$ falls slowly enough to match (and co-determine) the efflux $k_2 M_1$ by the influx $K_1 c$, whereby a quasi-steady state is maintained. This is the domain of validity of GP asymptotics.

For $k_2 < \beta$ we re-write (14):

$$\frac{M_1}{c} = \frac{K_1}{\beta - k_2} \left[e^{(\beta - k_2)t} - 1 \right] \quad (15)$$

As shown in Fig. 2 (upper curve), this M_1/c rises monotonically to infinity with t (and so with θ : Sect. 2). In this kinetic domain $c(t)$ falls ahead of M_1 so that $K_1 c$ cannot match $k_2 M_1$ to maintain proportionality of $M_1(t)$ to $c(t)$: the denominator of the GP ordinate M/c approaches zero faster than the numerator. The resulting growth of M/c with θ is unrelated to metabolism. In this domain the GP representation cannot be recommended for data analysis (Sect. 4). In Fig. 2 the two kinetic domains are separated by the line $M_1/c = K_1 t$ (case $k_2 = \beta$).

In the presence of metabolism the domain of validity of GP asymptotics and hence of (11) is defined by $k_2 + k_3 > \beta$ in place of $k_2 > \beta$ (see however end of Sect. 4). When $k_2 + k_3 < \beta$, the rise of M/c to infinity with t (and θ) is non-linear. The absence of the familiar asymptote in the presence of k_3 is due to non-metabolic terms (as in (15)), but it is apt to inspire modifications of the model (1) – (4) rather than a re-examination of its kinetics.

Exact calculations, in which the “final exponential” is replaced by a form $c(t)$ which is realistic at all times, reiterate the foregoing analysis.

Discussion

The possibility of time-reversal on the upslope of the plasma curve depends on experimental design (the site and rate of infusion: Sect. 2). In contrast, the validity of asymptotic GP analysis is not in the hands of the experimenter, but is determined by the interaction of each tracer with the ROI of the target organ (kinetic constants) as well as on its whole-body kinetics (downslope of $c(t)$).

The popularity of determining metabolic clearance K by linear regression to the GP asymptote (11) rests on its avoidance of determining all kinetic constants by non-linear regression requiring the inclusion of problematic early data: but then $k_2 + k_3$ is not available for comparison with β . If GP asymptotics such as (11) was used outside its domain of validity, the slope of the late rise of M/c with θ would simulate spurious metabolism ($k_3 = 0$) or miscalculate the rate of actual metabolism (see Appendix).

The widely used glucose analogue PET tracers (such as ^{11}C -methylglucose and ^{18}F -fluorodeoxyglucose) appear to be safely in the domain of validity of GP asymptotics, their kinetic constants and biological plasma activity decay having been established for organs such as the brain and the liver in humans and animals. In contrast, the magnitude (and even the existence) of a backflux of ^{13}N -ammonia from human brain is controversial (Ott and Larsen, 2004, Keiding *et al*, 2006), while avid uptake of ammonia in the body increases β after correcting $c(t)$ for metabolites (see Appendix II).

If k_2 is negligible as compared with k_3 , then k_3 cannot be determined from $M(t)$, $c(t)$: without an appreciable backflux, dynamic PET loses its grip on metabolism. To see this, we add (1) and (2), set $k_2 = 0$ and integrate:

$$M(t) = V_0 c(t) + K_1 \int_0^t c dt \quad (16)$$

which is independent of k_3 . Dividing (16) by $c(t)$ we see that (11) has become one straight line for all time, not merely an asymptote. Its intercept is the vascular volume V_0 , which in humans is of the order 0.2 mL cm^{-3} in the liver but less than 0.05 mL cm^{-3} in the brain. The intercepts in Fig.3, and in all our corresponding cases, are more than 20 times greater, putting the backflux of ammonia from the brain beyond doubt.

When k_2 is positive, (16) holds for early data before the onset of backflux (while k_2M_1 is negligible: recall $M_2(0)=0$ in (3)). Apart from microvascular heterogeneity, this time domain allows the simplest determination of K_1 . However, in dynamic PET the data sets $c(t)$, $M(t)$ are determined by two disparate experimental procedures: the times pertaining to blood samples must be synchronized on a joint time axis with the times of ROI activities recorded by the PET camera (Munk et al., 2003). Any asynchronism induces a spurious (positive or negative) increment of K_1 in response to a temporal mismatch of $c(t)$ and $M(t)$. The resulting errors are maximal when these observables are changing rapidly during the first passage of the tracer bolus through the ROI, but are greatly attenuated in later downslope processes (hence a robust GP asymptote).

The insensitivity of GP asymptotics to early data is particularly valuable in PET studies of the human liver with its dual blood supply. As sampling of the portal vein is not admissible in humans, the true input $c(t)$ is not available until hepatic arterial and portal venous tracer inputs are equalized by several recirculations. The quantitative effect of this circumstance on complete kinetic analyses has been demonstrated in animal experiments (Munk et al., 2001).

When $k_2 < \beta$, non-compartmental effects set in on the downslope of $c(t)$. Thus, in the course of washout from a once-through preparation of cat gastrocnemius muscle, k_2 dropped after 5 minutes to 1/5 of its initial value for sucrose, and to 1/2 for labeled water (Crone and Garlick, 1970). This phenomenon occurs when uncompensated efflux depletes tracer in the tissue close to the capillary membrane, so that rate-determination of the efflux is shifted increasingly from membrane permeability to transport along tissue concentration gradients of the tracer. To ensure that this non-compartmental time-dependence of k_2 does not invalidate the fitting of kinetic “constants” using (1) – (4), the inequality $k_2 > \beta$ must hold. This in turn implies the validity of the condition $k_2 + k_3 > \beta$ for

the validity of GP asymptotics. However, these conditions may not be sufficient to ensure constancy of k_2 when the ROI extends over slow and fast non-vascular subcompartments (Lassen and Perl, 1979).

Acknowledgements

We are grateful to Michael Sørensen, Albert Gjedde, Flemming Hermansen, and a referee for valuable discussions, and for the support of NIH grant R01-DK-074419.

Accepted manuscript

Appendix: Exactly soluble case

I. Derivation

To elucidate the Gjedde-Patlak representation of metabolism by an exactly soluble case, we choose a simple $c(t)$ declining along a single exponential after an initial step-rise:

$$\begin{aligned} c(t) &= 0 & , \text{ for } t < 0 \\ c(t) &= b e^{-\beta t} & , \text{ for } t \geq 0 \end{aligned} \quad (\text{A1})$$

where b and β are positive constants.

Then, from (5),

$$\theta = \frac{e^{\beta t} - 1}{\beta} \quad (\text{A2})$$

Using (A1) in (1)-(4), we calculate $M(t)$, and after replacing t with θ by means of (A2) we find

$$\frac{M}{c} - V_0 = K_1 \frac{k_3}{k_2 + k_3} \theta + V_r \left[1 - (1 + \beta \theta)^{\left(1 - \frac{k_2 + k_3}{\beta}\right)} \right] \quad (\text{A3})$$

where

$$V_r = \frac{K_1 k_2}{(k_2 + k_3)(k_2 + k_3 - \beta)} \quad (\text{A4})$$

which may be interpreted as the a reversible extravascular volume of distribution of a tracer. This is the GP representation of the kinetics (1)-(4) with input (A1), valid exactly for all $\theta \geq 0$. From it we deduce rigorously the late-time GP asymptotics including a corrected form of (11).

(a) Slow plasma decay: $(k_2+k_3)/\beta > 1$.

As θ grows to infinity, the last term in (A3) tends to zero because the exponent of $(1+\beta\theta)$ is negative. Thus we recover the GP asymptote (11) with the intercept corrected by the presence of β :

$$\frac{M}{c} - V_0 = K_1 \frac{k_3}{k_2 + k_3} \theta + V_r \quad (\text{A5})$$

with V_r given by (A4), so that the intercept is $V=V_0+V_r$. The approach to the asymptote depends on $(k_2+k_3)/\beta$. For example, if $k_2+k_3=2\beta$, then (A3)-(A4) becomes

$$\frac{M}{c} - V_0 = K_1 \frac{k_3}{k_2 + k_3} \theta + \frac{2K_1 k_2}{k_2 + k_3} \left[1 - \frac{1}{1 + \frac{k_2 + k_3}{2} \theta} \right] \quad (\text{A6})$$

the square bracket tends to 1 from below, and $V_r=2K_1 k_2/(k_2+k_3)^2$ as θ becomes large.

(b) Fast plasma decay: $(k_2+k_3)/\beta < 1$.

Here the exponent in (A3) is positive, and both the square bracket in (A3) and V_r in (A4) change sign:

$$\frac{M}{c} - V_0 = K_1 \frac{k_3}{k_2 + k_3} \theta + \frac{K_1 k_2}{(k_2 + k_3)(\beta - k_2 - k_3)} \left[(1 + \beta\theta)^{\left(1 - \frac{k_2 + k_3}{\beta}\right)} - 1 \right] \quad (\text{A7})$$

The last term increases non-linearly with θ : there is no asymptote. The form of increase depends on $(k_2+k_3)/\beta$. For example, if $(k_2+k_3)=\beta/2$, then (A7) becomes

$$\frac{M}{c} - V_0 = K_1 \frac{k_3}{k_2 + k_3} \theta + \frac{K_1 k_2}{(k_2 + k_3)^2} \left[\sqrt{1 + 2(k_2 + k_3)\theta} - 1 \right] \quad (\text{A8})$$

so that the “intercept” grows with large θ as $\theta^{1/2}$.

(c) The limiting case: $k_2+k_3=\beta$ divides the regimes (a) and (b). From (A3) and (A4), we obtain:

$$\frac{M}{c} - V_0 = K_1 \frac{k_3}{k_2 + k_3} \theta + \frac{K_1 k_2}{(k_2 + k_3)^2} \ln[1 + (k_2 + k_3)\theta] \quad (\text{A9})$$

At small θ all cases reduce to

$$\frac{M}{c} - V_0 = K_1 \theta \quad (\text{A10})$$

When $k_3=0$, we recover (14) and (15) with t replaced with θ by means of (A2).

II. Application to hepatic encephalopathy.

An important aspect of this disease is high plasma concentration of ammonia and slow biological decay of a bolus of ammonia tracer (small β), both resulting from deficient hepatic elimination of ammonia. Healthy subjects have distinctly lower plasma ammonia and faster biological decay of a tracer bolus (higher β).

When GP asymptotics is found to hold for cerebral kinetics of ammonia ($k_2+k_3>\beta$: Keiding *et al*, 2006), then the kinetic parameters K_1 , k_2 , k_3 , V_0 obtained from (1)-(4) by *non-linear* regression to *all* data determine the slope and the intercept of the asymptote (11) by full calculation. The same asymptote determined by *linear* regression to *late* data (Fig.3) yields the slope and intercept more directly (and robustly). The resulting slope is the same, but the intercept is higher than that calculated from (11).

For mono-exponential $c(t)$ this is apparent from the enhancement of V_r in (A4) by the subtraction of β in the denominator. This non-equilibrium effect persists for more realistic forms of $c(t)$. Denoting by V_{nl} the intercept obtained by non-linear regression, and by V_l that obtained by linear regression, we find in all subjects a systematic inequality $V_l > V_{nl}$ such that the ratio V_{nl}/V_l quantifies the degree of hepatic encephalopathy. This diagnostic coupling between hepatic and cerebral ammonia kinetics may be conveniently (though only approximately) thought of in terms of the magnitude of β in

(A4): the time-course of ammonia tracer in plasma is itself diagnostic (Sørensen and Keiding, 2006).

Fig. 3 shows GP representation of cerebral ammonia kinetics for a normal subject with arterial ammonia concentration of $20 \mu\text{mol/L}$ and $V_1 = 2.3 \text{ mL cm}^{-3}$ (upper curve), and for a patient with arterial ammonia concentration elevated to $41 \mu\text{mol/L}$ and $V_1 = 0.9 \text{ mL cm}^{-3}$ (lower curve). The smaller slope of the patient's asymptote is probably due to the relatively higher partial saturation of k_3 (glutamine synthetase: Ott and Larsen, 2004). The ratio V_n/V_1 in the patient is 0.65 in cortex, 0.74 in the basal region, and 0.68 in the cerebellum, with corresponding values 0.27, 0.35, 0.30 in the normal subject. A similar distinction is seen in all subjects who had $c(t)$ carefully corrected for metabolites of the tracer (Keiding et al, 2006), but not enough of these are currently available for standard tests of statistical significance.

Accepted manuscript

List of symbols

α, b	positive constants describing early plasma upslope in Eq.7.
β	exponential decay of $c(t)$
$c(t)$	input function i.e. activity concentration of blood entering the region (activity ml^{-1})
K	slope of the Gjedde-Patlak asymptote ($\text{ml ml}^{-1} \text{min}^{-1}$). In Eq.11, K is $K_1 k_3 / (k_2 + k_3)$
K_1	clearance of tracer from blood to M_1 ($\text{ml ml}^{-1} \text{min}^{-1}$)
k_2	rate constant for the efflux of tracer from M_1 (min^{-1})
k_3	rate constant for the transformation of tracer from M_1 to M_2 (min^{-1})
$M(t)$	total regional activity concentration as recorded externally by PET (activity ml^{-1})
$M_1(t)$	regional activity concentration in precursor pool (activity ml^{-1})
$M_2(t)$	regional activity concentration in metabolized pool (activity ml^{-1})
t	time (min)
t_p	time of the peak plasma activity (min)
$\theta(t)$	the Gjedde-Patlak transformed time variable (min)
V	$V = V_0 + V_r$ is the intercept of the Gjedde-Patlak asymptote (ml ml^{-1})
V_0	vascular volume in the region (ml ml^{-1})
V_l	is $V_0 + V_r$ (GP intercept) estimated by linear regression (ml ml^{-1})
V_{nl}	is $V_0 + V_r$ (GP intercept) calculated from parameters estimated by non-linear regression (ml ml^{-1})
V_r	volume of reversible components in the region (ml ml^{-1}) given by Eq.A4 or, with $\beta=0$ by $K_1 k_2 / (k_2 + k_3)^2$ in Eq.11

References:

- Bass L, Aisbett J, and Bracken AJ, 1984. Asymptotic forms of tracer clearance curves: theory and applications of improved extrapolations. *J Theor Biol* 111: 755-785.
- Bender D, Munk OL, Feng HQ, and Keiding S, 2001. Metabolites of ^{18}F -FDG and 3- ^{11}C -methylglucose in pig liver. *J Nucl Med* 42: 1673-1678.
- Crone C and Garlick D, 1970. The penetration of insulin, sucrose, mannitol and tritiated water from muscle into the vascular system. *J Physiol (Lond.)* 210: 387-404.
- Gjedde A, 1982. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. *Brain Res* 257 (2): 237-274.
- Keiding S, Sørensen M, Bender D, Munk OL, Ott P, and Vilstrup H, 2006. Brain metabolism of ^{13}N = ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. *Hepatology* 43: 42-50.
- Lassen NA and Sejrsen P, 1971. Monoexponential extrapolation of tracer clearance curves in kinetic analysis. *Circ Res* 29 (1): 76-87.
- Lassen NA and Perl W, 1979. Tracer Kinetic Methods in Medical Physiology. Raven Press, New York, Chapter 10.
- Munk OL, Bass L, Roelsgaard K, Bender D, Hansen SB, Keiding S, 2001. Liver kinetics of glucose analogs measured in pigs by PET: Importance of dual-input blood sampling. *J Nucl Med* 42:795-801.
- Munk OL, Keiding S, and Bass L, 2003. Capillaries within compartments: microvascular interpretation of dynamic positron emission tomography data. *J Theor Biol* 225: 127-141.
- Ott P and Larsen FS, 2004. Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. *Neurochem Int* 44: 185-198.
- Patlak CS, Blasberg RG, and Fenstermacher JD, 1983. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. *J Cereb Blood Flow Metab* 3 (1): 1-7.
- Phelps ME, Hoffman EJ, and Raybaud C, 1977. Factors which affect cerebral uptake and retention of $^{13}\text{NH}_3$. *Stroke* 8: 694-702.
- Raichle ME and Larson KB. 1981. The significance of the $\text{NH}_3\text{-NH}_4$ equilibrium on the passage of ^{13}N ammonia from blood to brain. A new regional residue detection model. *Circ Res* 48:913-937.
- Sørensen S, and Keiding S, 2006. Ammonia metabolism in liver cirrhosis. In: Hepatic Encephalopathy and Nitrogen Metabolism. Eds. Häussinger D, Kirchel G, and Schliess F, Eds.), Springer, 406-419.

FIGURE LEGENDS

Fig.1. Time-reversal seen in the falling part of the plot of transformed time θ against ordinary time t . The plot was made using Eq.8 and $\alpha=5\text{min}^{-1}$ describing the early plasma upslope (solid line). The remaining part of the plasma curve up to its peak at t_p is also shown (dashed line). Three different values of t (solid circles) correspond to any one value of θ in the interval $\theta_{\min}<\theta<\theta_{\max}$.

Fig.2. Non-metabolized tracer with kinetic parameters $K_1=0.15\text{ mL mL}^{-1}\text{ min}^{-1}$, $k_2=0.25\text{ min}^{-1}$. The Gjedde-Patlak (GP) ordinate is plotted against ordinary time for: a) slow plasma downslope (lower curve) using $\beta=0.175\text{ min}^{-1}$; b) rapid plasma downslope (upper curve) using $\beta=0.325\text{ min}^{-1}$. GP asymptotics holds for $k_2>\beta$, and the two domains are separated by the line $M_1/c=K_1 t$ corresponding to $k_2=\beta$.

Fig.3. Gjedde-Patlak (GP) plots of cerebral kinetics of ammonia tracer in a case of hepatic encephalopathy (lower curve) and in a normal subject (upper curve). The solid lines are GP asymptotes. The lower frame expands the early part of the upper frame. Both sets of measurements (circles) extend over 30 min of ordinary time. Within this time interval no reversal of the metabolizing step (which would have been seen as a concavity of the asymptote) is detectable.




FIGURE 1




FIGURE 2





FIGURE 3